Mizuho lowered the firm’s price target on Embecta (EMBC) to $12 from $13 and keeps a Neutral rating on the shares. The firm adjusted price targets in medical devices and diagnostics ahead of the Q2 reports.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EMBC:
- Embecta price target lowered to $13 from $15 at Mizuho
- Embecta price target lowered to $25 from $26 at BTIG
- Embecta Corporation’s Strategic Transition and Financial Outlook: A Buy Rating Based on Growth Initiatives and Attractive Valuation
- Embecta Unveils Strategy at Analyst and Investor Day
- Cautious Outlook on Embecta Corporation Amidst Unclear Growth Catalysts and Margin Concerns